Ozaki Kosuke, Kawai Kazushige, Ogawa Shimpei, Kanemitsu Yukihide, Ajioka Yoichi
Department of Gastroenterological Surgery, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Expert Rev Anticancer Ther. 2025 Jul;25(7):821-827. doi: 10.1080/14737140.2025.2506646. Epub 2025 May 15.
The optimal criteria for lateral lymph node dissection (LLND) in rectal cancer following neoadjuvant therapy remain undefined. This systematic review and meta-analysis evaluated the diagnostic accuracy of lateral lymph node metastasis (LLNM) to refine criteria for selective LLND.
A systematic search of PubMed, Embase, and the Cochrane Library (10 August 2024) identified studies assessing magnetic resonance imaging (MRI)-based LLNM detection in patients with rectal cancer who underwent neoadjuvant therapy and radical surgery. Studies reporting MRI-based LLNM assessments with pathological confirmation were included. Non-English studies, reviews, case reports, and those lacking lymph node size data were excluded. The risk of bias was assessed using QUADAS-2. Pooled sensitivity, specificity, and diagnostic odds ratios were estimated using hierarchical summary receiver operating characteristic curve (HSROC) analysis.
Eleven studies met the inclusion criteria. All used MRI-based size assessments. The pooled sensitivity and specificity were 0.776 (95% CI: 0.639-0.872) and 0.694 (95% CI: 0.541-0.813), respectively, with an HSROC area under the curve (AUC) of 0.801.
MRI is the most widely used modality for diagnosing LLNM in rectal cancer patients who have undergone neoadjuvant therapy, with size criteria being the most commonly applied.
PROSPERO (CRD42024578499).
新辅助治疗后直肠癌侧方淋巴结清扫(LLND)的最佳标准仍未明确。本系统评价和荟萃分析评估了侧方淋巴结转移(LLNM)的诊断准确性,以完善选择性LLND的标准。
对PubMed、Embase和Cochrane图书馆进行系统检索(截至2024年8月10日),以确定评估接受新辅助治疗和根治性手术的直肠癌患者基于磁共振成像(MRI)检测LLNM的研究。纳入报告基于MRI的LLNM评估且有病理证实的研究。排除非英文研究、综述、病例报告以及缺乏淋巴结大小数据的研究。使用QUADAS-2评估偏倚风险。采用分层汇总接受者操作特征曲线(HSROC)分析估计合并敏感性、特异性和诊断比值比。
11项研究符合纳入标准。均采用基于MRI的大小评估。合并敏感性和特异性分别为0.776(95%CI:0.639-0.872)和0.694(95%CI:0.541-0.813),HSROC曲线下面积(AUC)为0.801。
MRI是诊断接受新辅助治疗的直肠癌患者LLNM最广泛使用的方法,大小标准是最常用的标准。
PROSPERO(CRD42024578499)